Fondazione Policlinico Universitario Agostino Trials

Fondazione Policlinico Universitario Agostino	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lorusso, Domenica

innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting

502

Europe, Canada, Japan, US, RoW

tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed

Seagen, a wholly owned subsidiary of Pfizer, Genmab

Cervical Cancer

07/23

05/26

NItCHE, NCT04679064 / 2020-000146-33: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting

427

Europe

Niraparib, Zejula, Dostarlimab, TSR-042, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Topotecan, Bevacizumab, Avastin

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline

Ovarian Cancer

01/25

ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer

Recruiting

220

Europe, Canada, US, RoW

Selinexor, KPT-330, Matching Placebo for selinexor

Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group

Endometrial Cancer

01/25

01/28

LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting

132

Europe

Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2

Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary

09/29

MITO29, NCT03467178: Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Recruiting

119

Europe

Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin, Gemcitabine, Paclitaxel

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Recurrent, Platinum-resistant Ovarian Cancer

12/21

NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting

Europe, US, RoW

Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Ovarian Cancer

01/28

MITO25, NCT03462212: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Recruiting

1/2

290

Europe

Carboplatin, Paclitaxel, Bevacizumab, Rucaparib

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto Di Ricerche Farmacologiche Mario Negri, Foundation Medicine

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

03/25

FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1/2

210

Europe, US, RoW

CPI-0209

Constellation Pharmaceuticals

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma

12/25

03/26

PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting

1/2

230

Europe, US, RoW

rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79

PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC

Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer

03/26

07/26

BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting

240

Europe, Canada, Japan, US, RoW

GSK5733584

GlaxoSmithKline

Solid Tumors, Neoplasms

10/26

07/27

MITO 34, NCT04617470: Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study

Recruiting

N/A

300

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline

Ovarian Cancer

01/22

OVAL-1, NCT04532645: Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Completed

N/A

342

Europe

Olaparib, Lynparza

AstraZeneca

Ovary Cancer

09/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lorusso, Domenica

innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting

502

Europe, Canada, Japan, US, RoW

tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed

Seagen, a wholly owned subsidiary of Pfizer, Genmab

Cervical Cancer

07/23

05/26

Recruiting

427

Europe

Niraparib, Zejula, Dostarlimab, TSR-042, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Topotecan, Bevacizumab, Avastin

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline

Ovarian Cancer

01/25

ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer

Recruiting

220

Europe, Canada, US, RoW

Selinexor, KPT-330, Matching Placebo for selinexor

Endometrial Cancer

01/25

01/28

LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting

132

Europe

Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2

Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary

09/29

MITO29, NCT03467178: Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Recruiting

119

Europe

Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin, Gemcitabine, Paclitaxel

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Recurrent, Platinum-resistant Ovarian Cancer

12/21

NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting

Europe, US, RoW

Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Ovarian Cancer

01/28

Recruiting

1/2

290

Europe

Carboplatin, Paclitaxel, Bevacizumab, Rucaparib

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto Di Ricerche Farmacologiche Mario Negri, Foundation Medicine

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

03/25

FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1/2

210

Europe, US, RoW

CPI-0209

Constellation Pharmaceuticals

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma

12/25

03/26

PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting

1/2

230

Europe, US, RoW

rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79

PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC

Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer

03/26

07/26

BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting

240

Europe, Canada, Japan, US, RoW

GSK5733584

GlaxoSmithKline

Solid Tumors, Neoplasms

10/26

07/27

MITO 34, NCT04617470: Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study

Recruiting

N/A

300

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline

Ovarian Cancer

01/22

OVAL-1, NCT04532645: Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Completed

N/A

342

Europe

Olaparib, Lynparza

AstraZeneca

Ovary Cancer

09/24



	Diseases Companies Products Productz Mechanisms of Action Sites